Search

Your search keyword '"María del Carmen García-Carreira"' showing total 3 results
Start Over Author "María del Carmen García-Carreira"
3 results on '"María del Carmen García-Carreira"'

1. Inflammatory Response of Ischemic Tolerance in Circulating Plasma: Preconditioning-Induced by Transient Ischemic Attack (TIA) Phenomena in Acute Ischemia Patients (AIS)

Author

Laura Colàs-Campàs, Joan Farre, Gerard Mauri-Capdevila, Jessica Molina-Seguín, Núria Aymerich, Ángel Ois, Jaume Roquer, Silvia Tur, María del Carmen García-Carreira, Joan Martí-Fàbregas, Antonio Cruz-Culebras, Tomás Segura, Gloria Arque, and Francisco Purroy

Subjects
ischemic stroke, transient ischemic attack (TIA), plasma, ischemic preconditioning (IPC), endogenous neuroprotection, biomarker (BM), Neurology. Diseases of the nervous system, RC346-429
Abstract

Introduction: Ischemic tolerance (IT) refers to a state where cells are resistant to the damaging effects caused by periods of ischemia. In a clinical scenario, the IT phenomenon would be activated by a recent transient ischemic attack (TIA) before an ischemic stroke (IS). The characterization of inflammatory protein expression patterns will contribute to improved understanding of IT.Methods: A total of 477 IS patients from nine hospitals, recruited between January 2011 and January 2016, were included in the current study and divided in three groups: 438 (91.9%) patients without previous TIA (group 1), 22 (4.6%) patients who suffered TIA 24 h before IS (group 2), and 17 (3.5%) patients who suffered TIA between 24 h and 7 days prior to IS (group 3). An inflammatory biomarker panel (IL-6, NT-proBNP, hsCRP, hs-Troponin, NSE, and S-100b) on plasma and a cytokine antibody array was performed to achieve the preconditioning signature potentially induced by TIA phenomena. Primary outcome was modified rankin scale (mRs) score at 90 days.Results: Recent previous TIA was associated with better clinical outcome at 90 days (median mRS of group 1: 2.0 [1.0–4.0]; group 2: 2.0 [0.0–3.0]; group 3: 1.0 [0–2.5]; p = 0.086) and smaller brain lesion (group 1: 3.7 [0.7–18.3]; group 2: 0.8 [0.3–8.9]; group 3: 0.6 [0.1–5.5] mL; p = 0.006). All inflammation biomarkers were down regulated in the groups of recent TIA prior to IS compared to those who did not suffer a TIA events. Moreover, a cytokine antibody array revealed 30 differentially expressed proteins between the three groups. Among them, HRG1-alpha (Fold change 74.4 between group 1 and 2; 74.2 between group 1 and 3) and MAC-1 (Fold change 0.05 between group 1 and 2; 0.06 between group 1 and 3) expression levels would better stratify patients with TIA 7 days before IS. These two proteins showed an earlier inflammation profile that was not detectable by the biomarker panel.Conclusion: Inflammatory pathways were activated by transient ischemic attack, however the period of time between this event and a further ischemic stroke could be determined by a protein signature that would contribute to define the role of ischemic tolerance induced by TIA.

Published
2020
Full Text
View/download PDF

2. Ischemia preconditioning induces an adaptive response that defines a circulating metabolomic signature in ischemic stroke patients

Author

Joaquim Sol, Laura Colàs-Campàs, Gerard Mauri-Capdevila, Jessica Molina-Seguin, José Daniel Galo-Licona, Coral Torres-Querol, Núria Aymerich, Ángel Ois, Jaume Roquer, Silvia Tur, María del Carmen García-Carreira, Joan Martí-Fàbregas, Antonio Cruz-Culebras, Tomás Segura, Reinald Pamplona, Manel Portero-Otín, Gloria Arqué, Mariona Jové, and Francisco Purroy

Subjects
acute ischemic stroke, metabolomics, Stroke, Neurology, ischemic preconditioning, Ischemic Attack, Transient, Ischemia, Humans, lipidomics, Neurology (clinical), Prospective Studies, Cardiology and Cardiovascular Medicine, Transient ischemic attack, Ischemic Stroke
Abstract

Transient ischemic attacks (TIAs) before an acute ischemic stroke (AIS) could induce ischemic tolerance (IT) phenomena. with an endogenous neuroprotective role (Ischemic preconditioning. IPC). A consecutive prospective cohort of patients with AIS were recruited from 8 different hospitals. Participants were classified by those with non-previous recent TIA vs. previous TIA (within seven days. TIA ≤7d). A total of 541 AIS patients were recruited. 40 (7.4%). of them had previous TIA ≤7d. In line with IPC. patients with TIA ≤7d showed: 1) a significantly less severe stroke at admission by NIHSS score. 2) a better outcome at 7–90 days follow-up and reduced infarct volumes. 3) a specific upregulated metabolomics/lipidomic profile composed of diverse lipid categories. Effectively. IPC activates an additional adaptive response on increasing circulation levels of structural and bioactive lipids to facilitate functional recovery after AIS which may support biochemical machinery for neuronal survival. Furthermore. previous TIA before AIS seems to facilitate the production of anti-inflammatory mediators that contribute to a better immune response. Thus. the IT phenomena contributes to a better adaptation of further ischemia. Our study provides first-time evidence of a metabolomics/lipidomic signature related to the development of stroke tolerance in AIS patients induced by recent TIA.

Published
2022

3. Impact of COVID-19 Infection on the Outcome of Patients With Ischemic Stroke

Author

Alejandro Bustamante, Ana Rodríguez-Campello, Mikel Vicente, Antia Moreira, Meritxell Gomis, Mercè Salvat, Joan Martí-Fàbregas, Luis Mena, Ana Núñez-Guillén, Luis Prats-Sánchez, Josep Zaragoza, María Del Carmen García-Carreira, Marta Rubiera, Pol Camps-Renom, Angel Ois, Saima Bashir Viturro, Francisco Purroy, Manuel Gómez-Choco, Marta Olivé, Patricia Esteve, Xavier Ustrell, Marta Almeria, Laura Llull, Cecile van Eendenburg, Oriol Barrachina, Raquel Delgado-Mederos, Natalia Pérez de la Ossa, Pere Cardona, Dolores Cocho, Javier Codas, Esther Catena, Marina Guasch-Jiménez, Laia Seró, Manuel Requena, Joaquín Serena, E. Palomeras, Alejandro Martínez-Domeño, Gislaine Castilho de Oliveira, Daniel Guisado-Alonso, Sergio Amaro, and Jerzky Krupinski

Subjects
Male, Original Contributions, Stroke severity, coronavirus, medicine.disease_cause, Severity of Illness Index, Thrombolytic Therapy, Prospective Studies, Stroke, Thrombectomy, Coronavirus, Aged, 80 and over, Age Factors, Middle Aged, Prognosis, stroke, cerebrovascular disease, reperfusion, thrombectomy, ComputingMethodologies_DOCUMENTANDTEXTPROCESSING, Female, Cardiology and Cardiovascular Medicine, medicine.medical_specialty, 2019-20 coronavirus outbreak, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), pandemics, Clinical and Population Sciences, Internal medicine, medicine, Humans, In patient, Mortality, Aged, Ischemic Stroke, Advanced and Specialized Nursing, SARS-CoV-2, business.industry, Anticoagulants, COVID-19, medicine.disease, Functional Status, Logistic Models, Case-Control Studies, Multivariate Analysis, Ischemic stroke, Neurology (clinical), prognosis, business
Abstract

Supplemental Digital Content is available in the text., Background and Purpose: We evaluated whether stroke severity, functional outcome, and mortality are different in patients with ischemic stroke with or without coronavirus disease 2019 (COVID-19) infection. Methods: A prospective, observational, multicentre cohort study in Catalonia, Spain. Recruitment was consecutive from mid-March to mid-May 2020. Patients had an acute ischemic stroke within 48 hours and a previous modified Rankin Scale (mRS) score of 0 to 3. We collected demographic data, vascular risk factors, prior mRS score, National Institutes of Health Stroke Scale score, rate of reperfusion therapies, logistics, and metrics. Primary end point was functional outcome at 3 months. Favourable outcome was defined depending on the previous mRS score. Secondary outcome was mortality at 3 months. We performed mRS shift and multivariable analyses. Results: We evaluated 701 patients (mean age 72.3±13.3 years, 60.5% men) and 91 (13%) had COVID-19 infection. Median baseline National Institutes of Health Stroke Scale score was higher in patients with COVID-19 compared with patients without COVID-19 (8 [3–18] versus 6 [2–14], P=0.049). Proportion of patients with a favourable functional outcome was 33.7% in the COVID-19 and 47% in the non-COVID-19 group. However, after a multivariable logistic regression analysis, COVID-19 infection did not increase the probability of unfavourable functional outcome. Mortality rate was 39.3% among patients with COVID-19 and 16.1% in the non-COVID-19 group. In the multivariable logistic regression analysis, COVID-19 infection was a risk factor for mortality (hazard ratio, 3.14 [95% CI, 2.10–4.71]; P

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results